Proteomics International has an unparalleled scientific and commercial team from a diverse range of backgrounds. The team has skills in all aspects of protein chemistry encompassing the cutting edge of mass spectrometry to traditional methods and more.
Richard has extensive experience in analysing biomolecules by proteomics techniques, in particular mass spectrometry, including over 25 years research experience in academic and commercial organisations. As a founding Director and Managing Director of Proteomics International Richard has overseen the commercial and technical development of the organisation. Previously he was Manager of the core Protein Analysis Facility at the University of Western Australia, following a post-doctoral position at the Institute for Child Health Research. He is company trained in the use of MALDI-TOF MS and LC/MS/MS (including TOF/TOFs and ion-traps), and further expertise/training in Edman sequencing, peptide synthesis, and robotics for proteomics.
1995 PhD (Immunology), University of London (Institute of Child Health)
1991 Certificate in Immunology, Kings College, University of London
1990 MA and BA (Chemistry), Corpus Christi College, Oxford University
Jacqueline is a Senior Finance Executive with over 25 years of experience in multiple industries and managing companies with a global turnover in excess of £500M. She has a successful track record with developing & implementing corporate strategy, building high performance management teams, M&A and post-merger integration. Jacqueline is currently serving as CFO & Head of Human Resources for Proteomics International and has held numerous senior management positions with Healthcare of Australia, The Economist Group, BBC Worldwide and Arthur Andersen. Most recently, Jacqueline has been working with several emerging ASX listed companies in the medical technology, SaaS, digital marketing, e commerce, retail and renewables sectors.
Graduate Diploma in Applied Corporate Governance,
Governance Institute of Australia
Chartered Accountant, Institute of Chartered Accountants
Vik has over 25 years of experience in the life sciences and healthcare sectors as a commercialisation expert and business strategy advisor for several multinational, growth-stage & startup medical device and biopharmaceutical companies. He has been involved in the product launch of numerous disruptive medical technologies, cutting-edge biotherapies and innovative healthcare business process outsourcing solutions to penetrate new and emerging markets.
Most recently, Vik served as interim Chief Executive Officer for surgical software startup ClaraSim Systems (via Stanford University, USA) and has previously held senior positions with IQVIA MedTech (IMS Health + Quintiles), BioFuse Medical and Deloitte Consulting – Healthcare & Life Sciences as well as sales, marketing and business development roles at Ascension Orthopaedics, TissueLink Surgical, Serono Laboratories and Wyeth Pharmaceuticals.
QualificationsBachelor of Science (Marketing), Southern Illinois University, USA
Chuck has over 35 years of Business Development & Corporate Strategy experience in the life sciences, diagnostic and biotechnology industries. He has held several senior management positions with NEN Life Sciences and DuPont Medical before focusing his last 15 years in corporate development at PerkinElmer. Chuck has successfully executed several strategic licensing, distribution & partnership deals and has completed multiple global acquisitions. Mr. Morrison currently serves on the Board of Directors with Avisa Pharma and XCR Diagnostics as well as a Senior Advisor for Outcome Capital. Chuck is based in Boston, Massachusetts, USA.
BA (Chemistry), College of the Holy Cross, Massachusetts, USA
Scott is responsible for all Research areas within Proteomics International. This involves oversight of Biomarker discovery and development projects encompassing PromarkerD, PI’s predictive test for diabetic nephropathy. Alongside the biomarker research program is the development and implementation of novel methods for examining biological systems (particularly venoms) for discovery of novel therapeutic peptides where genomic/ proteomic information is unavailable or incomplete. He also leads the development of new chromatographic and mass spectrometric methods for handling of complex biological samples for analysis and investigation.
Scott has a commercial background as proteomics scientist and mass spectrometry specialist at a New Zealand based R&D company, now part of AgResearch. This was preceded by a Post-Doctoral Fellowship at the National Cancer Institute, USA, looking at bioactive protein isolation, purification and identification of both anti-cancer and anti-HIV leads from marine sources. Scott’s skills are wide ranging and include expertise with mass spectrometers, liquid chromatography, assay development and bioinformatic analysis.
PhD, Department of Chemistry, University of Canterbury
BSc (Hons), Department of Chemistry, University of Canterbury
Pearl is responsible for coordinating and ensuring the commercial delivery of PromarkerD and the Promarker™ pipeline. Pearl has extensive experience in management and research commercialisation. Her previous roles include Chief Operating Officer of Proteomics International, Business Manager (PromarkerD), and leading the commercialisation of the patented 2-tag technology (used to measure oxidative stress). Pearl has a background in research and completed her PhD in Biochemistry and Molecular Biology at The University of Western Australia. She has been with Proteomics International since 2013.
PhD (Research), Biochemistry and Molecular Biology, UWA
BSc with honours in Biochemistry, UWA, Australia
BSc, Molecular Biology and Biotechnology, UWA, Australia
Mike brings over 25 years of Sales Leadership experience in the medical device and diagnostic arena, from innovative start-ups to best-in-class market leaders. He has extensive experience managing national sales teams, both with direct employee based teams and external distribution partners for the USA market, along with a product launch portfolio ranging from breakthrough innovations to well established medical technologies.
Mr. LeFauve recently served as Vice President of Sales at Ethos Laboratories with additional oversight of marketing, sales operations and corporate sales training. Prior to Ethos Labs, he held senior management roles at Theragen and DJO Global. Mike resides in Charlotte, North Carolina, USA.
Bachelor of Science (Marketing), Canisius College, USA
Kirsten has over 15 years of experience in clinical and genetic epidemiology. Kirsten leads the clinical studies and biostatistics team at Proteomics International, responsible for the development and validation of PromarkerD and diagnostics in the Promarker™ pipeline. She has been with the company for over 7 years and has been a Consultant at the University of Western Australia for 15 years. Kirsten has extensive experience in data analysis and has co-authored over 40 peer-reviewed journal articles.
PhD (Research), Medical Sciences, JCSMR, ANU, Australia BSc with honours in Medical Sciences, UON, Australia
BSc in Molecular Biology and Medical Sciences, UON, Australia
Sreeja brings 14 years of Sales & Business Development experience in the medical technology and pharmaceutical sectors. She has handled operations, logistics, technical support and purchasing activities in her previous roles. Sreeja has substantial experience selling life sciences services, consumables and instruments to a wide range of clients across the biopharma space.
Sreeja joined Proteomics International in 2016 and was recently appointed to Business Manager of the company’s Analytical Services business unit.
Post Graduate Diploma in Business Management-Marketing, NMIMS, India
MSc in Biotechnology, PTU, India
BSc in Biotechnology, Bangalore University, India